![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 9, 6490-6498, March 3, 2000
From the Type I signal peptidases are integral membrane
proteins that function to remove signal peptides from secreted and
membrane proteins. These enzymes carry out catalysis using a
serine/lysine dyad instead of the prototypical
serine/histidine/aspartic acid triad found in most serine proteases.
Site-directed scanning mutagenesis was used to obtain a qualitative
assessment of which residues in the fifth conserved region, Box E, of
the Escherichia coli signal peptidase I are critical for
maintaining a functional enzyme. First, we find that there is no
requirement for activity for a salt bridge between the invariant
Asp-273 and the Arg-146 residues. In addition, we show that the
conserved Ser-278 is required for optimal activity as well as conserved
salt bridge partners Asp-280 and Arg-282. Finally, Gly-272 is essential
for signal peptidase I activity, consistent with it being located
within van der Waals proximity to Ser-278 and general base Lys-145
side-chain atoms. We propose that replacement of the hydrogen side
chain of Gly-272 with a methyl group results in steric crowding,
perturbation of the active site conformation, and specifically,
disruption of the Ser-90/Lys-145 hydrogen bond. A refined model is
proposed for the catalytic dyad mechanism of signal peptidase I in
which the general base Lys-145 is positioned by Ser-278, which in turn is held in place by Asp-280.
The majority of proteins exported from a cell are made with a
signal or leader peptide. These peptides are responsible for targeting
proteins to the cytoplasmic membrane in prokaryotes and the endoplasmic
reticulum membrane in eukaryotes (1-3). The protein is then
translocated across the membrane, and the N-terminal peptide is removed
from the pre-protein by a type I signal peptidase.
SPase I1 has been isolated from Gram-negative (4-6) and
Gram-positive (7, 8) bacteria as well as
from several eukaryotic organisms (9-12). These endopeptidases are
membrane-bound and specific for the region within the signal peptide
immediately preceding the cleavage site. The substrate protein is
cleaved during or after the protein is transported across the membrane bilayer. Cleavage occurs by way of nucleophilic attack by a catalytic serine O The best-studied enzyme of this family is SPase I, or leader peptidase,
of Escherichia coli. It has been cloned (13), sequenced (14), and purified (15, 16). Its substrate specificity has been
characterized; small-uncharged residues at the P1 ( The recent crystal structure (27) of the catalytic domain of SPase I
(28-29) has revealed that most of the amino acids that are strictly
conserved in Boxes B, C, D, and E of the signal peptidase family (30)
are found to be located near the active site (see Fig. 1A).
In E. coli, the Box B conserved region contains the catalytic serine (Ser-90), and Box D contains the catalytic lysine (Lys-145). Box E contains the conserved GDN (Gly-272, Asp-273, and
Asn-274 in E. coli), Ser-278, Asp-280, and Arg-282 (Fig.
1B). In this work, we have employed a scanning mutagenesis
approach to obtain a qualitative assessment of which residues in the
conserved Box E are critical for maintaining a functional SPase I. We
find that Ser-278, which contributes a hydrogen bond to Lys-145 and therefore helps position this residue, is critical for activity. In
addition, substitution of Gly-272 with an alanine leads to a marked
effect on activity. Gly-272 most likely plays a structural role,
because it is located adjacent to the catalytic Ser-90 and Lys-145
dyad. Any side chain other than hydrogen at 272 results in steric
crowding and perturbation of the active site. Asp-280 and Arg-282 are
also important for SPase I activity. Asp-280, which forms a hydrogen
bond to Ser-278, may help to position the general base Lys-145.
Finally, the salt bridge between Asp-273 and Arg-146 is not required
for activity.
Bacterial Strains and Plasmids--
E. coli
BLR(DE3) [F DNA Methods--
The SPase I gene, lepB, was cloned
into the pET23b vector by excising the lepB gene from the
pING plasmid (33) by digestion with SalI and
SmaI. The lepB gene fragment was then ligated
into a modified pET23b vector containing an SmaI site that
was created upstream of the T7 termination region and containing a
72-base deletion of the T7 tag sequence. The final construct, pET23lep, contains the wild-type lepB gene modified with a
six-histidine sequence at codons 35-40 (22). Oligonucleotide
mutagenesis was performed using the Quikchange mutagenesis kit
(Stratagene). Mutations were verified by plasmid isolation and
sequencing (Sequenase Version 2.0). The calcium chloride method was
used for DNA transformations into E. coli host strain
BLR(DE3) (34).
Purification of 6-His-tagged Signal Peptidase
Proteins--
SPase I mutants containing a 6-His tag were purified
using ion exchange and nickel affinity chromatography (35). Since SPase I, with a pI of 6.9, has only a weak affinity for Q-Sepharose ion
exchange resin, a semi-pure dilute sample was obtained after the first
chromatographic step. The nickel column served to further purify as
well as concentrate the SPase I enzyme. Three liters of culture was
sufficient to obtain approximately 3 mg of >95% pure protein for a
majority of the mutants made.
Overnight cultures of E. coli BLR(DE3) cells harboring the
pET23lep vector encoding the SPase I proteins were back-diluted 1:40 in
3 liters of LB media with 100 µg/ml ampicillin and 12.5 µg/ml
tetracycline and grown at 37 °C to an absorbance of 0.6 at 600 nm.
Expression was then induced by the addition of IPTG to a final
concentration of 0.5 mM. Growth of the culture was continued for an additional 4 h, after which the cells were
harvested by centrifugation and resuspended in 25 ml of lysis buffer
(50 mM Tris, pH 8.0, 20% sucrose). Lysozyme (6 mg) and
RNase-free DNase (Promega) (60 µl at 10 mg/ml) were added, and the
solution was stirred for 10 min followed by freezing at Purification of the pro-OmpA Nuclease A Substrate--
E.
coli strain BL21(DE3) containing pro-OmpA nuclease A encoded in
the pET-21a plasmid was used for overexpression of the pre-protein
substrate. The pro-OmpA nuclease A was expressed and purified as
described by Chatterjee et al. (36).
In Vitro Activity Assay Using pro-OmpA Nuclease A--
To
determine the enzymatic activity of wild-type and mutant SPase I, we
used pro-OmpA nuclease A as a substrate. Cleavage of this substrate was
performed at different SPase I dilutions. The Pierce BCA protein assay
was used to determine the concentrations of purified SPase I
constructs, and an E1% at 280 nm of 8.3 was
used to determine the concentration pro-OmpA nuclease A (36). The
starting concentration of each SPase I mutant for the dilution study
was 0.1 mg/ml. Aliquots (1 µl) of enzyme (0.1, 0.01, 0.001, 0.0001, and 0.00001 mg/ml) were added to 15 µl of substrate at a final
concentration of 15 µM in 50 mM Tris, pH 8.0, 1% Triton X-100. The reaction was incubated at 37 °C for 1 h
then stopped by the addition of 4 µl of 5-fold sample buffer followed
by quenching in a dry ice-ethanol bath. Processing of the pre-protein
substrate to its mature nuclease A form was monitored by 17.2%
SDS-PAGE.
In Vivo SPase I Activity Assay--
The activity of SPase I
in vivo was determined using the temperature-sensitive
E. coli signal peptidase strain, IT41 (31). The procedure is
the same as described by Sung and Dalbey (37) with the following
modifications. IT41 was grown at 30 °C in M9 minimal medium (38) at
pH 7.0 with 0.5% fructose and 50 µg/ml each amino acid except
methionine with either wild-type SPase I or a mutated version of this
enzyme in the IPTG-inducible plasmid, pET23lep. At mid-log phase, cells
were grown at 42 °C for 1 h to inactivate the intrinsic
temperature-sensitive SPase I. IPTG was added to a final concentration
of 1 mM to induce synthesis of the mutant SPase I and
incubated at 42 °C for an additional 30 min. Cell cultures (1 ml)
were labeled with 200 µCi of [35S]methionine for
15 s and chased with nonradioactive methionine at a final
concentration of 500 µg/ml. At indicated times, aliquots (100 µl)
were removed and quenched with an equal volume of ice-cold 20%
trichloroacetic acid. Processing of the precursor to the outer membrane
protein A (pro-OmpA) was used to determine the in vivo activity of the SPase I mutants. Proteins were immunoprecipitated with
antibody to outer membrane protein A (15) and analyzed by SDS-PAGE and
fluorography (39).
Circular Dichroism (CD) Spectroscopy--
Circular dichroism
measurements were conducted on a Jasco spectrapolarimeter J-500C
instrument using a temperature-controlled cell at 4 °C. Protein
concentrations of each SPase I construct were determined by using a
molar extinction coefficient of 44,000 cm Western Blot Analysis--
BLR (DE3) (2 ml) harboring the
pET23lep plasmid was grown in LB media to an absorbance at 600 nm of
0.7, then induced with IPTG (final concentration of 1 mM).
After an additional 3-h incubation at 37 °C, cell cultures (100 µl) were normalized by dilution to the indicated final cell densities
at A600 and were pelleted and resuspended in
2-fold sample buffer. Aliquots (10 µl) of dissolved cell extracts
were then analyzed by 17.2% SDS-PAGE. The expression levels of the
SPase I mutants were compared with the expression levels of wild-type
SPase I. To do this, 10 µl of 1.1, 0.22, and 0.11 A600 units of cells containing overexpressed
wild-type protein were assayed by 17.2% SDS-PAGE. The protein samples
were electroblotted onto nitrocellulose membranes and visualized
following the ECL Western blot protocol (Amersham Pharmacia Biotech).
Pulse-chase Assays--
BLR(DE3) cultures (2 ml) were grown and
induced the same manner as the Western blot protocol, except M9 media
was used containing 0.5% fructose and all amino acids (50 µg/ml
each) except methionine. After a 1-h induction, cells were labeled with
100 µCi of [35S]methionine for 1 min and chased with an
excess of nonradioactive methionine (500 µg/ml final concentration).
Portions (100 µl) were removed at the indicated time points and added
to ice-cold 20% trichloroacetic acid. Samples were then
immunoprecipitated (15) and analyzed by SDS-PAGE and fluorography
(39).
Structural Analysis--
Hydrogen bonding contacts within the
x-ray crystal structure of the E. coli SPase I soluble
fragment (PDB 1b12) were analyzed with the program CONTACT (CCP4, 1994).
The x-ray crystal structure of the catalytic fragment of SPase I
(27) has revealed potentially important amino acid residues located
near the active site (Fig.
1A). This information coupled with knowledge of residues conserved in both prokaryotic SPase I and
eukaryotic SPase I homologs enabled the rational design of mutants. In
this work, we have focused on the conserved Box E region of the signal
peptidase family (Fig. 1B). Box E contains the conserved
tripeptide, GDN (Gly-272, Asp-273, and Asn-274 in E. coli),
as well as the conserved Ser-278, Asp-280, and Arg-282 residues (in
E. coli). Glycine and aspartate in the GDN consensus are
strictly conserved, and the asparagine is highly conserved in all type
I SPases. Ser-278 is only conserved in prokaryotic, mitochondrial SPase
I (Imp1/Imp2) and the chloroplast thylakoid processing peptidase
(chloroplast SPase I). We have constructed a number of mutants to test
the importance of these residues and measured activity in
vitro using the substrate pro-OmpA nuclease A. Mutants with a
significant reduction in substrate processing were further analyzed
in vivo, and their contribution to the structure and protein
stability of the enzyme were also examined.
To increase protein expression over the original pING construct (33)
the SPase I gene was cloned into the pET23b vector. The increased
expression was needed for the two-part purification procedure employing
ion exchange and nickel affinity chromatography (see "Experimental
Procedures") (35) in order to obtain higher yields of pure mutant
SPase I. With this new protocol the purity of each mutant (Fig.
2, lanes 1-11 and
13-14) is comparable with that of the wild-type enzyme
(lane 12). For purposes of CD spectroscopic analysis, the
nickel affinity column was also used to exchange the detergent Triton
X-100 for the non-UV-absorbing
The Role of the Conserved Box E Residues in the Active Site of
the Escherichia coli Type I Signal Peptidase*
,
§,
,
,
¶,
**,

, and
§§
Department of Chemistry, The Ohio State
University, Columbus, Ohio 43210 and
Department of Biochemistry
and Molecular Biology, University of British Columbia,
Vancouver V6T 1Z3, British Columbia, Canada
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
on the peptide bond between the presequence and the mature
region of the pre-protein.
1) and P3 (
3)
positions of the substrate are required for cleavage (17-19). SPase I
utilizes a serine/lysine dyad mechanism to perform its enzymatic
function rather than the canonical catalytic triad found in most serine
proteases (20-23). To date, only a few other enzymes, such as LexA
(24), UmuD (25), and the Tsp protease (26) have been identified with
this unusual active site mechanism. Additional analysis is required to
provide insight into other residues near this dyad in the SPase family
and the roles they play, if any, in the structure and function of these enzymes.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
ompT
hsdSB(rB
mB
)
gal dcm (srl-recA)
306::Tn10 (DE3)], BL21(DE3)
[F
ompT
hsdSB(rB
mB
) gal
dcm (DE3)], and the pET21a and pET23b vectors were obtained from
Novagen. E. coli IT41, a temperature-sensitive SPase I
strain, was obtained from Dr. Yoshikazu Nakamura (31). The pING plasmid (32), which contains SPase I under the araB promoter (33), was from Dr.
Gary Wilcox (Ingene, Inc.)
80 °C
overnight. The lysed cells were thawed, and 200 µl of 1 M
magnesium acetate was added and mixed by stirring for 10 min at room
temperature. The solution was then centrifuged at 20,000 rpm for 30 min
at 4 °C, and the pellet was resuspended in 25 ml of 10 mM triethanolamine, 10% glycerol, pH 7.9. After
centrifugation, the pellet was resuspended by douncing in
solubilization buffer (10 mM triethanolamine, 10% glycerol, 1% Triton X-100, pH 7.9) and re-centrifuged a third time.
The SPase I-rich supernatant was loaded onto a 15-ml Q-Sepharose column
(Amersham Pharmacia Biotech) previously equilibrated in solubilization
buffer. The column was washed with 20 ml of solubilization buffer plus
5 mM magnesium sulfate, pH 7.9, and SPase I was eluted with
a continuous gradient of 0-0.1 M KCl in column buffer.
Two-ml fractions were collected and assayed for SPase I protein by
SDS-PAGE. Fractions containing the enzyme were pooled and loaded onto a 1-ml nickel nitrilotriacetic acid-agarose column (Qiagen) equilibrated with 6-His buffer (10 mM Tris, pH 8.5, 100 mM
KCl, 20 mM imidazole, 10 mM
-mercaptoethanol, 1% detergent (either Triton X-100 or
-D-octylglucopyranoside). The column was then washed
with 7 ml of 6-His buffer and 1 ml of wash buffer (6-His buffer plus
900 mM KCl). SPase I was then eluted using a 100 to 300 mM imidazole step gradient. Eluted fractions were assayed
for SPase I protein by SDS-PAGE followed by GelCode Blue staining
(Pierce). To remove the imidazole, pooled proteins were dialyzed
against 20 mM Tris, pH 8.0, 0.5% Triton X-100 or buffer
exchanged with a Centricon-10 membrane (Amicon) using 20 mM
phosphate, 1%
-D-octylglucopyranoside, pH 8.0.
1
M
1 at 280 nm (21).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (28K):
[in a new window]
Fig. 1.
Active site region of E. coli
SPase I with the conserved Box E residues. A,
ball and stick representation of the active site
residues of E. coli SPase I. This figure was made with the
program PREPI. B, sequence alignment of Box E domain
conserved in the type I SPase family. Within the consensus motif,
uppercase indicates strictly conserved residues;
lowercase indicates conservative substitutions;
Lep, leader peptidase (or signal peptidase); Eco,
E. coli; Sty, Salmonella typhimurium;
Pfl, Pseudomonas fluorescens; Hin,
Haemophilus influenzae; Pla,
Phormidium laminosum; Syn6a,
Synechocystis sp. PCC6803; Bja,
Bacillus japonicum; Bsu, B. subtilis; Bam, Bacillus
amyloliquefaciens; Bli, Bacillus
licheniformis; Bca, Bacillus caldolyticus;
Sau, Staphylococcus aureus; Spn,
Streptococcus pneumoniae; Mtu,
Mycobacterium tuberculosis; Rca,
Rhodobacter capsulatus; Imp, inner membrane
protease; Tpp, thylakoidal processing peptidase;
Ath, Arabidopsis thaliana; Sip, signal
peptidase; Mja, Methanococcus jannaschii;
Mth, M. thermoautotrophicum; Pho,
Pyrococcus horikoshii; Spc, signal peptidase
complex.
-octylglucopyranoside. Lanes
10, 11, and 12 in Fig. 2 are preparations in
which this detergent exchange method was applied.

View larger version (35K):
[in a new window]
Fig. 2.
SDS-PAGE analysis of purified 6-His SPase I
proteins. Proteins were resolved on a 17.2% polyacrylamide gel
followed by GelCode Blue staining (Pierce). Lane 1, N274A;
lane 2, N274D; lane 3, T94V; lane 4,
R146A; lane 5, R146M; lane 6, S281A; lane
7, G285A; lane 8, N277A; lane 9, N277D;
lane 10, S278A; lane 11, G272A; lane
12, wild-type; lane 13, D273E; lane 14,
T94V/R146A. Proteins in lanes 1-9, 13, and
14 were solubilized with the detergent Triton X-100.
Proteins in lanes 10-12 were solubilized with the detergent
-D-octylglucopyranoside. MW, molecular
mass.
Many Conserved Residues in the Vicinity of the Active Site Are Not
Important for Enzymatic Activity or Stability--
Wild-type 6-His
SPase I processes pro-OmpA nuclease A to mature nuclease A even at a
10,000-fold dilution of a 0.1 mg/ml stock solution (Fig.
3, bottom right panel). SPase
I enzymes with the single mutations T94V, R146A, R146M, G285A, N277A,
and N277D all maintained activity out to 104-fold dilution,
indicating these residues were not critical for catalysis. Since amino
acid substitutions at these positions had little, if any, catalytic
effect, further studies were not performed. Although the S281A enzyme
showed a 100-fold decrease in activity, we also did not investigate
this residue further because it is not conserved in all type I SPases
and because mutation of the homologous serine residue in the
Bacillus subtilis SipS enzyme had very little affect on
activity (40).
|
The Serine at Position 278 Is Essential for Optimal Activity--
In vitro and in vivo activity data for the
S278A SPase I mutant is shown in Fig. 4.
The mutation of Ser-278 to an Ala would remove the hydrogen bond from
Ser-278 to the catalytic Lys-145 (Fig. 1A; See Table
I for H-bond distances). This alteration leads to a significant loss of catalytic activity in vitro.
Processing of the pro-OmpA nuclease A substrate by this mutant
exhibited a 300-fold decrease as compared with the wild-type enzyme
(Fig. 4A). The activity of the Ser-278 mutant was also
assayed using the more sensitive in vivo assay, where SPase
I activity was measured in its native membrane environment. This assay
examines whether the plasmid-encoded S278A SPase I can restore
processing of pro-OmpA at the nonpermissive temperature of 42 °C in
the temperature-sensitive SPase I strain, IT41 (31). Fig. 4B
demonstrates that the processing of pro-OmpA by E. coli
SPase I is slowed at the nonpermissive temperature of 42 °C in IT41
bearing no plasmid, with an approximate t1/2 of
60 s. In contrast, processing of pro-OmpA is rapid
(t1/2 < 10 s) at 42 °C when it contains the
pET23lep vector encoding wild-type 6-His SPase I. IT41 containing a
plasmid-encoding signal peptidase S278A exhibited slow processing of
pro-OmpA when compared with wild-type. The t1/2 for
the S278A enzyme is between 20 and 30 s. Immunoblot analysis
indicates that the signal peptidase S278A mutant is expressed within
the cell in comparable amounts as wild-type (data not shown). These
in vitro and in vivo results demonstrate that the
Ser-278 residue is required for rapid SPase I processing.
|
|
To rule out global structural changes in SPase I due to the S278A
mutation, we employed CD spectroscopy. Both S278A SPase I and the
wild-type enzyme retain identical spectra between 200 and 250 nm (Fig.
5), providing evidence that the S278A
protein is not grossly misfolded. Thus, the decrease in activity is
consistent with and attributable to the loss of the hydrogen bonding
capability of Ser-278 to Lys-145.
|
Glycine 272 in the Conserved GDN Is Critical for
Activity--
Since Gly-272, Asp-273, and Asn-274 are conserved and in
the vicinity of the active site near the catalytic Lys-145 (27), we
investigated their impact on catalysis. In vitro
studies of G272A and N274A signal peptidases are shown in Fig.
6. The exchange of an alanine for an
asparagine at position 274 had little effect on substrate processing
(Fig. 6A, bottom panel). In contrast, substitution of the glycine at position 272 to alanine led to a marked
effect on in vitro processing (Fig. 6A, top
panel). Quantitation of the pro-OmpA nuclease A processing by gel
band densitometry for the G272A mutant indicated that processing was
impaired roughly 750-fold relative to wild-type enzyme (data not
shown).
|
We also analyzed SPase I G272A protein for activity in intact cells. As can be seen in Fig. 6B, SPase I G272A has impaired in vivo processing of pro-OmpA in IT41 at 42 °C (t1/2 ~ 50 s), consistent with the in vitro results. Again, the global structural integrity of this SPase I protein appeared unperturbed as demonstrated by the CD spectrum (Fig. 5).
The Salt Bridge between Aspartic Acid 273 and Arginine 146 Is Not Required for Activity of the E. coli SPase I-- The x-ray structure has revealed that aspartic acid 273 forms a salt bridge with arginine 146 and a hydrogen bond with threonine 94 (Fig. 1A). To assess the significance of these interactions, we first mutated Asp-273 to alanine or asparagine. Since sufficient amounts of the Asp-273 mutants could not be purified because of the lowered expression levels and the failure to solubilize the SPase I mutant from the membrane with detergent,2 we measured the activity of the Asp-273 mutants in vivo. In Fig. 6B it is evident that the D273A (middle panel) and D273N (bottom panel) SPase I mutants have impaired processing in vivo. The processing activity at 42 °C is only slightly better with these mutants than when no plasmid is present (Fig. 4B). The processing t1/2 of the D273A and D273N enzymes are close to 30 s. This demonstrates that the aspartic acid residue at position 273 is required for efficient SPase I activity when its interacting salt bridge partner, Arg-146, is also present.
As a control, we tested whether the decreased in vivo
activity results from lower expression levels within the cell. The
amount of signal peptidase expressed was determined by Western blotting using SPase I antiserum. As can be seen in Fig.
7, both SPase I D273A and D273N are
expressed at approximately one-fifth the level as pET23lep-encoded
wild-type SPase I. Decreased expression levels of Asp-273 mutants may
contribute slightly to the lower processing of pro-OmpA to mature OmpA
in IT41 at the nonpermissive temperature.
|
The residues Arg-146 and Thr-94, which interact with Asp-273, were
mutated to amino acids with nonpolar side chains. To our surprise, the
double mutant T94V/R146A maintained almost full activity (Fig.
8A), demonstrating that
neither the salt bridge between Asp-273 and Arg-146 nor the
Thr-94/Asp-273 hydrogen bond is required (Fig. 1A, Table I).
Moreover, SPase I is still functional when the Asp-273 residue is
conservatively replaced with a glutamic acid side chain (Fig.
8A).
|
To test the requirement for an acidic side chain at position 273 even in the absence of its salt bridge partner, we mutated both the Asp-273 and Arg-146 residues simultaneously. In Fig. 8B, in vivo processing is more rapid in the mutants that contain substitutions both at Arg-146 and Asp-273 (D273A/R146A and D273A/R146A/T94V) versus only the single (D273A) mutant (Fig. 6B). Taken together, the results indicate that the Asp-273 and Arg-146 salt bridge is not required for activity, and the acidic Asp-273 is only required when the basic Arg-146 is present as well.
Aspartic Acid 280 and Arginine 282 Mutations Affect Optimal
Activity--
The E. coli SPase I crystal structure (27)
indicates the carboxylate oxygen of Asp-280 is about 5.0Å from the
catalytically important N
of Lys-145 (Fig. 1A). The
homologous residue to Asp-280 was found to be critical for activity in
B. subtilis (40) as well as eukaryotic yeast Sec11 (41)
SPase I. The functional role of Asp-280 was examined in our E. coli system. D280A and D280E mutants of E. coli SPase I
were constructed and expressed, but purification of these proteins
proved rather difficult. Purification trials of the Asp-280 variants
resulted in proteins exhibiting lower concentration with evidence of
proteolytic degradation (Fig. 9A). Compared with wild-type
enzyme at similar concentrations, the D280A and D280E mutants
maintained more than a 1000-fold reduction in activity in
vitro (Fig. 9B). With the in vivo assay,
however, the D280A and D280E mutants of E. coli SPase I
demonstrated much higher activity levels (Fig. 9C). The
D280A and D280E mutants displayed slightly less in vivo
activity than wild-type (Fig. 4B) but greater activity than
the S278A and G272A mutants (Figs. 4B and 6B).
Pulse-chase analysis indicates that the Asp-280 mutants are stable
in vivo (Fig. 9D), and immunoblot analysis (data
not shown) was used to verify that the lower molecular bands of
purified D280A and D280E (Fig. 9A) were fragments of the
Asp-280 mutants.
|
To further study the role of Asp-280 in maintaining a functional SPase,
its ionic interacting partner, Arg-282, was also examined via an R282M
mutant. Purification of this Arg-282 variant resulted in a protein of
lower concentration than wild-type enzyme but with less degradation
than the Asp-280 mutants (Fig. 9A). Like the Asp-280
mutants, the R282M mutant displayed significantly less activity
in vitro compared with wild-type (Fig. 9, B and C). Also, the R282M mutant displayed greater in
vivo than in vitro activity but not as dramatic as the
Asp-280 mutants.
| |
DISCUSSION |
|---|
|
|
|---|
Previous studies have established that the catalytic mechanism of E. coli SPase I requires an essential Ser-90 (37) and Lys-145 (20, 21). The Paetzel et al. (27) crystal structure of the inhibitor-bound soluble fragment of E. coli SPase I has provided the first direct evidence of the nucleophilic nature of Ser-90 and a glimpse of the neighboring residues in the active site. In the consensus sequence of the SPase I family, Ser-90 of the E. coli enzyme is found in the second conserved domain (Box B), whereas the catalytic Lys-145 is in the fourth conserved domain (Box D). One of the most prominent aspects of the crystal structure was the fact that the entire fifth conserved domain (Box E) of E. coli SPase I was found in the active site area. This Box E consensus sequence contains a cluster of three residues, GDN (beginning with Gly-272), the conserved Ser-278, the strictly conserved Asp-280, and the conserved Arg-282.
In the present study, we show that Asn-277, Gly-285, and Thr-94, are not important for in vitro substrate processing. This suggests that these residues are not important for enzymatic function. Although mostly conserved in the bacterial SPases, the homologous subunits (i.e. Sec11, Spc18, and Spc21) in the eukaryotic endoplasmic reticulum signal peptidase do not share the same conservation at these positions. The toleration of these changes with respect to activity is therefore not unexpected.
In contrast, Ser-278 is necessary for efficient enzymatic action, as
demonstrated by the in vitro and in vivo
processing studies (Fig. 4). Serine 278 is conserved only in the
bacterial, mitochondrial (Imp1/Imp2), and chloroplast type I signal
peptidases (thylakoid-processing peptidases) that utilize the Ser/Lys
dyad (20, 21). The Ser-278 homolog is not present in archae SPases or
the endoplasmic reticulum subunit (Fig. 1B), which most
likely uses a Ser/His dyad (41). The crystal structure of the E. coli SPase I-soluble fragment (27) has revealed that S278O
contributes a key hydrogen bond to the Lys-145 N
atom (Fig. 1,
A and B; Table I) and is most likely essential
for directing the N
into its proper orientation. This would explain
why this Ser is conserved in type I SPases proposed to act by a Ser/Lys
mechanism and its absence in Ser/His type I SPases.
Our evidence of an in vivo and in vitro stable S278A enzyme coupled with an apparently correct conformation as evidenced by similar solubility, purification, and CD spectral properties compared with wild-type enzyme points to the loss of activity of S278A as being attributable to the loss of the critical hydrogen bonding interaction that facilitates the proper orientation of the catalytic Lys-145. Sequence alignment of SPase I with SipS of B. subtilis shows Ser-151 aligned with the E. coli Ser-278. Mutation of Ser-151 to an alanine strongly reduced the in vivo activity of SipS, although it still had demonstrable activity compared with mutations of the catalytic Ser and Lys residues (40).
In addition to Ser-278, the Box E domain of E. coli SPase I
contains Gly-272, Asp-273, and Asn-274, which are conserved in both
prokaryotic and eukaryotic organisms. Gly-272 and Asp-273 are strictly
conserved, whereas Asn-274 is a less conserved residue. Mutation of
Asn-274 to an Ala had no effect on SPase I activity (Fig.
6A). This result is consistent with the studies of B. subtilis Type I SPase (40). The in vitro and in
vivo data presented here is consistent with Gly-272 being critical
for SPase I activity. Analysis of the SPase I crystal structure (Fig.
1A; Table I) shows that Gly-272 is located within van der
Waals distance to the catalytic Lys-145 side chain. These two residues
are packed such that the introduction of a side chain other than Gly at
position 272 would force the Lys to shift from its optimal position and potentially cause local perturbations in the active site. Again the
lack of evidence for gross structural changes based on stability, solubility, CD measurements, and ease of isolation of the G272A mutant
leads us to conclude that the effects seen with G272A are solely due to
the local perturbations mentioned. The mutation of the homologous Gly
residue in the B. subtilis SipS signal peptidase, Gly-145,
to an alanine residue significantly decreases in vivo processing of pre-
-lactamase to its mature form (40). As with the
E. coli enzyme, the Gly in the GDN consensus of B. subtilis SipS is more critical for activity than the Ser-151,
(corresponding to E. coli Ser-278).
It is noteworthy that the decrease in E. coli SPase I activity due to mutation of the Ser-278 and Gly-272 residues was not as severe as with the substitutions of the catalytic Ser-90 and Lys-145 (37, 21, 22). No detectable in vivo activity was observed when Ser-90 and Lys-145 were mutated. Additionally there was no activity detected over background with the in vitro assay, which has a sensitivity of at least 100,000-fold. Thus mutations of the catalytic Ser-90 and Lys-145 residues cause a decrease in activity of greater than 100,000-fold.
We also show here there is no absolute requirement for activity for either the salt bridge between the invariant Asp-273 and Arg-146 residues or the hydrogen bond interaction between Asp-273 and Thr-94. First, substitution of Arg-146 with alanine or methionine has no effect on in vitro activity. Second, SPase I lacking both Arg-146 and Thr-94 was fully active in vitro. Third, SPase I lacking the Asp-273/Arg-146 salt bridge (D273A/R146A or D273A/R146A/T94V SPase I mutants) was active in vivo.
It is interesting that SPase I with the single Asp-273 mutation (either alanine or asparagine) was impaired in processing using the highly sensitive in vivo assay. This is in contrast to the double or triple mutant with the mutated Asp-273 residue above. It is not clear why the D273A or D273N mutants are inactive in vivo. It may be that these mutants are poorly expressed (Fig. 8) or may not fold or assemble into the membrane properly. Our data do not address this latter possibility. Unfortunately, the D273A and D273N mutants could not be purified and studied in vitro due to the poor expression as well as the difficulty in extracting these proteins from the membrane fraction with detergent. Nevertheless, the fact that the double and triple mutants (Fig. 8B), which remove Asp-273, are active demonstrates that there is not an absolute requirement for the Asp-273 residue.
Our results with the Arg-146 and Asp-273 substitutions in E. coli SPase I are in sharp contrast to those in B. subtilis or in yeast. Mutation of the homologous Asp-273 or Arg-146 residue in the B. subtilis SPase I or in the Sec11 subunit of the endoplasmic reticulum SPase I resulted in proteolytic degradation of these enzymes in vivo (40, 41), indicating that these residues are required for maintaining a stable, protease-resistant conformation. In our experiments the E. coli enzyme proved to be more stable in vivo, which was perhaps attributable to as yet unidentified compensating factors. Last, Bolhuis et al. (42) demonstrate thermal inactivation of the corresponding Arg-146/Asp-273 mutant of B. subtilis SipS (R84/D146), but the E. coli mutants (R146A or R146A/T94V) maintained identical activity as the wild-type protein at 37 °C and 42 °C in our in vivo experiments.2
Along with its salt bridge partner, Arg-282, the invariant Asp-280 residue of E. coli SPase I has been found to be important for enzymatic activity. The Asp-280 mutants are found to be stable in vivo (Fig. 9D) and display slightly lower processing than wild-type in vivo. R282M is also stable (not shown) but exhibits less in vivo activity than the Asp-280 mutants. Although mutations of Asp-280 affect activity, the E. coli SPase I is nevertheless quite active. Our in vivo Asp-280 results are in contrast to those results of van Dijl et al. (40) for the homologous residue in the B. subtilis SipS enzyme that is found to be absolutely critical for processing.
These studies are consistent with Asp-280 and Arg-282 being important for maintaining a fully functional E. coli SPase I enzyme. Unfortunately, we were not able to determine whether these residues are important for maintaining the structural integrity of the enzyme or play a direct catalytic role, since we were not able to purify the protein in sufficient amounts for structural and catalytic characterization. However, we favor the idea that it plays a structural role, because the x-ray crystal structure revealed that not only is Asp-280 held firmly in place by a strong salt bridge to Arg-282, but that it hydrogen bonds to Ser-278 and interacts with the main chain of Gly-272 and Arg-282 as well (Fig. 1A, Table I). The hydrogen bonding of Asp-280 to Ser-278 also likely aids the Ser-278 H-bonding interaction with the catalytic Lys-145.
The results of these studies have allowed us to refine our model of the
catalytic details of the Ser/Lys mechanism of SPase I as well as
explain the conserved nature of many of the Box E residues. Residues
Ser-278 and Asp-280 help position the general base Lys-145 residue.
Ser-278 contributes a hydrogen bond directly to the epsilon amino group
of the catalytic Lys-145 and, therefore, helps orient it with respect
to the catalytic Ser-90. The Gly-272 residue is located very near the
catalytic dyad and has been maintained through evolution. The studies
of Gly-272 presented here are consistent with the crystal structure of
SPase I, which reveals that any residue with a C
atom at the 272 position would sterically interfere with the Lys-145 side chain.
| |
ACKNOWLEDGEMENT |
|---|
Special thanks goes to Don Ordaz at the Ohio State University Department of Microbiology Bio-fermentation Facility for the large-scale E. coli preps.
| |
FOOTNOTES |
|---|
* This work was supported in part by National Institutes of Health Grant GM 48805 (to R. E. D.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Funded by National Institutes of Health Pre-doctoral Training Grant GM 08512.
¶ Present address: Dept. of Molecular Cancer Biology and Biochemistry, Duke University Medical Center, Durham, North Carolina 27710-3686.
** Funded by a Medical Research Council of Canada post-doctoral fellowship.

Funded by the Canadian Bacterial Diseases Network of Excellence
and the Burroughs Wellcome Foundation.
§§ To whom correspondence should be addressed. Tel.: 614-292-2384; Fax: 614-292-1532; E-mail: dalbey@chemistry.ohio-state.edu.
2 P. A. Klenotic, J. L. Carlos, J. C. Samuelson, T. A. Schuenemann, W. R. Tschantz, M. Paetzel, N. C. J. Strynadka, and R. E. Dalbey, unpublished data.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
SPase I, signal
peptidase I;
IPTG, isopropyl-1-thio-
-D-galactopyranoside;
PAGE, polyacrylamide gel electrophoresis.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Wickner, W., Dreissen, A. J., and Hartl, F.-U. (1991) Annu. Rev. Biochem. 60, 101-124[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Pugsley, A. P.
(1993)
Microbiol. Rev.
57,
50-108 |
| 3. | Dalbey, R. E., and Robinson, C. (1999) Trends Biochem. Sci. 24, 17-22[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Zwizinski, C.,
and Wickner, W.
(1980)
J. Biol. Chem.
255,
7973-7977 |
| 5. | van Dijl, J. M., van den Bergh, R., Revers, T., Smith, H., Bron, S., and Venema, G. (1990) Mol. Gen. Genet. 223, 233-240[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Black, M. T., Munn, J. G. R., and Allsop, A. E. (1992) Biochem. J. 282, 539-543 |
| 7. | van Dijl, J. M., de Jong, A., Vehmaanpera, J., Venema, G., and Bron, S. (1992) EMBO J. 11, 2819-2828[Medline] [Order article via Infotrieve] |
| 8. |
Cregg, K. M.,
Wilding, I.,
and Black, M. T.
(1996)
J. Bacteriol.
178,
5712-5718 |
| 9. |
YaDeau, J. T.,
and Blobel, G.
(1989)
J. Biol. Chem.
264,
2928-2934 |
| 10. | Baker, R. K., and Lively, M. O. (1987) Biochemistry 26, 8561-8567[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Greenburg, G.,
Shelness, G. S.,
and Blobel, G.
(1989)
J. Biol. Chem.
264,
15762-15765 |
| 12. | Schneider, A., Behrens, M., Scherer, P., Pratje, E., Michaelis, G., and Schatz, G. (1991) EMBO J. 10, 247-254[Medline] [Order article via Infotrieve] |
| 13. |
Date, T.,
and Wickner, W.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
6106-6110 |
| 14. |
Wolfe, P. B.,
Wickner, W.,
and Goodman, J. M.
(1983)
J. Biol. Chem.
258,
12073-12080 |
| 15. |
Wolfe, P. B.,
Silver, P.,
and Wickner, W.
(1982)
J. Biol. Chem.
257,
7898-7902 |
| 16. | Tschantz, W. R., and Dalbey, R. E. (1994) Methods Enzymol. 244, 285-301[Medline] [Order article via Infotrieve] |
| 17. |
Kuhn, A.,
and Wickner, W.
(1985)
J. Biol. Chem.
260,
15914-15918 |
| 18. |
Fikes, J. D.,
Barkocy-Gallagher, G. A.,
Klapper, D. G.,
and Bassford, P. J., Jr.
(1990)
J. Biol. Chem.
265,
3417-3423 |
| 19. | Shen, L. M., Lee, J.-I., Cheng, S., Jutte, H., Kuhn, A., and Dalbey, R. E. (1991) Biochemistry 30, 11775-11781[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Black, M. T.
(1993)
J. Bacteriol.
175,
4957-4961 |
| 21. |
Tschantz, W. R.,
Sung, M.,
Delgado-Partin, V. M.,
and Dalbey, R. E.
(1993)
J. Biol. Chem.
268,
27349-27354 |
| 22. |
Paetzel, M.,
Strynadka, N. C. J.,
Tschantz, W. R.,
Casareno, R.,
Bullinger, P.,
and Dalbey, R. E.
(1997)
J. Biol. Chem.
272,
9994-10003 |
| 23. | Paetzel, M., and Dalbey, R. E. (1997) Trends Biochem. Sci 22, 28-31[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Roland, K. L.,
and Little, J. W.
(1990)
J. Biol. Chem.
265,
12828-12835 |
| 25. | Peat, T. S., Frank, E. G., McDonald, J. P., Levine, A. S., Woodgate, R., and Hendrickson, W. A. (1996) Nature 380, 727-730[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Keiler, K. C.,
and Sauer, R. T.
(1995)
J. Biol. Chem.
270,
28864-28868 |
| 27. | Paetzel, M., Dalbey, R. E., and Strynadka, N. C. J. (1998) Nature 396, 186-190[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Kuo, D. W., Chan, H. K., Wilson, C. J., Griffin, P. R., Williams, H., and Knight, W. B. (1993) Arch. Biochem. Biophys. 303, 274-280[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Tschantz, W. R., Paetzel, M., Cao, G., Suciu, D., Inouye, M., and Dalbey, R. E. (1995) Biochemistry 35, 3935-3941 |
| 30. | Dalbey, R. E., Lively, M. O., Bron, S., and van Dijl, J. M. (1997) Protein Sci. 6, 1129-1138[Abstract] |
| 31. |
Inada, T.,
Court, D. L.,
Ito, K.,
and Nakamura, Y.
(1989)
J. Bacteriol.
171,
585-587 |
| 32. | Johnson, S., Lee, J. H., and Ray, D. S. (1985) Gene (Amst.) 34, 137-145[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Dalbey, R. E.,
and Wickner, W.
(1985)
J. Biol. Chem.
260,
15925-15931 |
| 34. | Cohen, S. N., Chang, A. C. Y., and Han, L. (1973) Proc. Natl. Acad. Sci. U. S. A. 69, 2110-2114 |
| 35. |
Smith, M. C.,
Furman, T. C.,
Ingolia, T. D.,
and Pidgeon, C.
(1988)
J. Biol. Chem.
263,
7211-7215 |
| 36. | Chatterjee, S., Suciu, D., Dalbey, R. E., Kahn, P. C., and Inouye, M. (1995) J. Mol. Biol. 245, 311-314[CrossRef][Medline] [Order article via Infotrieve] |
| 37. |
Sung, M.,
and Dalbey, R. E.
(1992)
J. Biol. Chem.
267,
13154-13159 |
| 38. | Miller, J. H. (1972) Experiments in Molecular Genetics , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 39. |
Ito, K.,
Date, T.,
and Wickner, W.
(1980)
J. Biol. Chem.
255,
2123-2130 |
| 40. |
van Dijl, J. M.,
de Jong, A.,
Venema, G.,
and Bron, S.
(1995)
J. Biol. Chem.
270,
3611-3618 |
| 41. |
van Valkenburg, C.,
Chen, X.,
Mullins, C.,
Fang, H.,
and Green, N.
(1999)
J. Biol. Chem.
274,
11519-11525 |
| 42. |
Bolhuis, A.,
Tjalsma, H.,
Stephenson, K.,
Harwood, C. R.,
Venema, G.,
Bron, S.,
and van Dijl, J. M.
(1999)
J. Biol. Chem.
274,
15865-15868 |
This article has been cited by other articles:
![]() |
M. F. Mazzeo, A. Sorrentino, M. Gaita, G. Cacace, M. Di Stasio, A. Facchiano, G. Comi, A. Malorni, and R. A. Siciliano Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for the Discrimination of Food-Borne Microorganisms Appl. Envir. Microbiol., February 1, 2006; 72(2): 1180 - 1189. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Karla, M. O. Lively, M. Paetzel, and R. Dalbey The Identification of Residues That Control Signal Peptidase Cleavage Fidelity and Substrate Specificity J. Biol. Chem., February 25, 2005; 280(8): 6731 - 6741. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Bardy, S. Y. M. Ng, D. S. Carnegie, and K. F. Jarrell Site-Directed Mutagenesis Analysis of Amino Acids Critical for Activity of the Type I Signal Peptidase of the Archaeon Methanococcus voltae J. Bacteriol., February 1, 2005; 187(3): 1188 - 1191. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Botos, E. E. Melnikov, S. Cherry, J. E. Tropea, A. G. Khalatova, F. Rasulova, Z. Dauter, M. R. Maurizi, T. V. Rotanova, A. Wlodawer, et al. The Catalytic Domain of Escherichia coli Lon Protease Has a Unique Fold and a Ser-Lys Dyad in the Active Site J. Biol. Chem., February 27, 2004; 279(9): 8140 - 8148. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Paetzel, R. E. Dalbey, and N. C. J. Strynadka Crystal Structure of a Bacterial Signal Peptidase Apoenzyme. IMPLICATIONS FOR SIGNAL PEPTIDE BINDING AND THE SER-LYS DYAD MECHANISM J. Biol. Chem., March |